ArticleVascular health and risk management2025
Predictive Utility of PLR and Platelet-to-LDL Ratio for in-Stent Restenosis Following Carotid Artery Stenting.
Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carotid artery stenting (CAS) has been widely used to remodel the vascular structure and restore the blood flow for preventing ischemic stroke. However, in-stent restenosis (ISR) after CAS is extremely associated with an increased risk of ischemic stroke recurrence. Objective: The aim of this study was to explore potential predict biomarkers for ISR after CAS. Methods: In this study, data from 221 patients with CAS, which was divided into no-ISR group and ISR group, and 145 healthy controls were retrospectively analyzed. The ratios of neutrophil, lymphocyte, monocyte, platelet, glucose (Glu), and triglyceride (TG) to lymphocyte, HDL, and LDL were analyzed, respectively. In addition, the ratios of SII, SIRI, and AISI were analyzed as the following formulas: SII = platelet × neutrophil-to-lymphocyte ratio, SIRI = monocyte × neutrophil-to-lymphocyte ratio, and AISI = neutrophil × platelet × monocyte-to-lymphocyte ratio. ROC curve analysis was performed to analyze the predict roles of PLR and platelet/LDL for ISR. Results: The ratios of NLR, PLR, Glu/lymphocyte, TG/lymphocyte, NHR, PHR, Glu/HDL, TG/HDL, neutrophil/LDL, platelet/LDL, Glu/LDL, TG/LDL, and SII increased in patients with CAS, indicating the predict roles of these values in carotid artery stenosis. Most importantly, increased ratios of PLR and platelet/LDL before the first operation of CAS, but not the second operation, were found in ISR patients after CAS as compared with no-ISR group. ROC analysis showed a more effective role of PLR for predicting ISR. While PLR showed high specificity (96.95%), its modest sensitivity (35.29%) suggests the need for complementary biomarkers in clinical practice. Conclusion: These results indicate that ratios of PLR and platelet/LDL before the first CAS operation can act as the predict biomarkers of ISR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.